Details of the Drug Reposition

General Information of This Drug (ID: DM376WT)

Drug Name
NKTR 214   DM376WT

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sarcoma DISZDG3U 2A60-2C35 Phase 2 [2]
------------------------------------------------------------------------------------
4 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
Colorectal cancer DISNH7P9 2B91.Z Phase 1/2 [3]
Renal cell carcinoma DISQZ2X8 2C90 Phase 1/2 [3]
Bladder cancer DISUHNM0 2C94 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)